ArticleFrontiers in immunology2020
Association of Urine sCD163 With Proliferative Lupus Nephritis, Fibrinoid Necrosis, Cellular Crescents and Intrarenal M2 Macrophages.
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Biomarkers of Lupus Nephritis Histopathology: Where Do We Stand?Arthritis & rheumatology (Hoboken, N.J.) · 2026Pooled it
- Urine proteomic insights from the belimumab in lupus nephritis trial.Lupus science & medicine · 2022Trial
- Tubulointerstitial inflammation in glomerular diseases: mechanistic pathways, prognostic value, and translational therapeutic targets.Renal failure · 2026Review
- CD163: a potential biomarker for lupus nephritis activity.Lupus science & medicine · 2026Article
- Serum and urinary soluble CD163 in children with active lupus nephritis.Pediatric rheumatology online journal · 2026Article
- Measurements of urinary biomarkers at 2 years following a lupus nephritis flare are associated with subsequent renal outcomes.Lupus science & medicine · 2026Article
- Urine proteins reveal distinct coagulation and complement cascades underlying acute versus chronic lupus nephritis.The Journal of clinical investigation · 2025Article
- Biomarkers in Lupus Nephritis: An Evidence-Based Comprehensive Review.Life (Basel, Switzerland) · 2025Review
- Clinical Predictors of Underlying Histologic Activity in Patients with Lupus Nephritis: A Focus on Urinary Soluble CD163.Journal of clinical medicine · 2025Article
- Soluble urine activated leukocyte cell adhesion molecule is a strong predictor of lupus nephritis.Rheumatology (Oxford, England) · 2025Article
- Molecular and Cellular Mediators of Renal Fibrosis in Lupus Nephritis.International journal of molecular sciences · 2025Review
- Increased CD163+ Macrophage Activation and High Expression of CD163 Promote Granulosa Cell Apoptosis in Polycystic Ovary Syndrome.Journal of inflammation research · 2025Article
- Scavenger receptors: key players in the immunological puzzle of lupus.Frontiers in lupus · 2025Article
- Inflammation in glomerular diseases.Frontiers in immunology · 2025Review
- Urinary biomarkers for active Lupus Nephritis that have survived independent validation across cohorts.Kidney international · 2024Review
- Urinary soluble CD163 is useful as "liquid biopsy" marker in lupus nephritis at both diagnosis and follow-up to predict impending flares.Journal of translational autoimmunity · 2024Article
- Urinary Biomarkers for Lupus Nephritis: A Systems Biology Approach.Journal of clinical medicine · 2024Review
- Macrophage subpopulations in pediatric patients with lupus nephritis and other inflammatory diseases affecting the kidney.Arthritis research & therapy · 2024Article
- Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis.JCI insight · 2024Article
- sCD163, sCD28, sCD80, and sCTLA-4 as soluble marker candidates for detecting immunosenescence.Immunity & ageing : I & A · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
CD163 is a marker for alternatively activated macrophages, which have been implicated in the pathogenesis of lupus nephritis (LN). In our preliminary screening of urine proteins in LN, urine soluble CD163 (sCD163) was significantly elevated in patients with active LN. To evaluate the potential of sCD163 as a biomarker in LN, urine sCD163 was assayed in patients with active LN, active non-renal lupus patients (ANR), inactive SLE and healthy controls (HC), using ELISA and normalized to urine creatinine. The correlation of urine sCD163 with clinical parameters and renal pathological attributes was further investigated in LN patients with concurrent renal biopsies. A total of 228 SLE patients and 56 HC were included from three cohorts. Results demonstrated that urine sCD163 was significantly elevated in active LN when compared with HC, inactive SLE, or ANR in African-American, Caucasian and Asian subjects (all
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.